Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Price History
|
Ratios
|
Insiders
Bullboard - Stock Discussion Forum
Hoth Therapeutics Inc
HOTH
Healthcare
Biotechnology
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell...
derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer’s or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State Universi...
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Bullboard (NDAQ:HOTH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(235)
•••
coolfooldumbguy
X
Post by
coolfooldumbguy
on Sep 02, 2025 9:53am
Buy buddy buy.
Otherwise it will be FOMO time for you fellas out there today anyway,so good luck to all
(744)
•••
7Twiggy
X
Post by
7Twiggy
on Jul 30, 2025 5:02pm
Back in
Back in today. Saw what could happen with REPL
(744)
•••
7Twiggy
X
Post by
7Twiggy
on Mar 04, 2025 1:26pm
HOTH
2025-03-04 18:08:00 GMT DJ Hoth Therapeutics Price Target Maintained With a $5.00/Share by D. Boral Capital
(476)
•••
Iseneschal
X
Comment by
Iseneschal
on Jan 07, 2025 9:57am
RE:HOTH ....ripping on NR
Like I said....Til it doesn't ; )
(476)
•••
Iseneschal
X
Post by
Iseneschal
on Jan 07, 2025 9:24am
HOTH ....ripping on NR
Til it doesn't
(744)
•••
7Twiggy
X
Post by
7Twiggy
on Jan 01, 2025 1:37pm
I am looking for a home run
They are involved in cancer therapies, weight loss control, alzheimers, just to name a few. Any one of these programs could hit the ball out of the park IMO. Risky for sure, but great
...more
(744)
•••
7Twiggy
X
Post by
7Twiggy
on Dec 31, 2024 1:32pm
Tax loss selling over
Tax selling over. My hope is we will see two or more big announcements that hould move the stock to triple digits.
(744)
•••
7Twiggy
X
Post by
7Twiggy
on Nov 01, 2024 1:14pm
Promising results on a number of fronts, alzheimer's, skin c
The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT
...more
(744)
•••
7Twiggy
X
Post by
7Twiggy
on Oct 16, 2024 3:06pm
This could be huge
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway HOTH
...more
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 27, 2024 2:00pm
New Press Release - Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
NEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,500,000 shares of...
read article.
(0)
•••
PressRelease
X
Post by
PressRelease
on Mar 27, 2024 8:28am
New Press Release - Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
Merveille.ai Files Patent for Obesity Treatment, Begins Preparatory Steps for Clinical Trials, Joins Nvidia Developer ProgramNEW YORK, March 27, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant...
read article.
(476)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 19, 2024 11:37am
HOTH...vols have all but dried up
if you were a gambler...might take a position here at $1.27 Not me...going skiing ; )
(476)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 19, 2024 11:13am
HOTH....Green to Red move.....
Wait for it
(476)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 19, 2024 11:03am
HOTH...you've all been had...again !
Same chit.....different pile
(476)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 19, 2024 11:01am
HOTH....almost 18 million shares have traded....
and all u get is 20 cents???? Whats wrong with this picture?????
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
{{previousButtonTitle}}
{{nextButtonTitle}}
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Environmental technology company enters a new strategic phase focused on scale and profitability